Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Evansville, Indiana 47710


This trial will be conducted in the United States of America (USA). The aim of the trial is to investigate whether the drug is safe, well tolerated and to investigate the efficacy of NNC 0070-0002-0182 for the treatment of obesity. The subjects will be treated with drug and placebo. This registration covers the phase 2 part of a combined phase 1/phase 2 trial (phase 1 part of trial conducted between November 2007 and April 2008).


Inclusion Criteria: - Body mass index (BMI) between 30.0-39.0 kg/m2 (obese) - Females who consent to using double barrier method of contraception, are post-menopausal and older than 50 years, or have had total hysterectomy Exclusion Criteria: - Clinically significant diseases - Blood pressure greater than 140/90 mmHg - Evidence of depression - Recent diet attempts, treatment with diet drugs (within 3 months) - Liposuction or other surgery for weight loss within the last year - Evidence of eating disorders (bulimia, binge eating) - Restricted diets (Kosher, vegetarian) - Smoker or history of drug or alcohol abuse - Females of childbearing potential: positive pregnancy test



Primary Contact:

Study Director
Global Clinical Registry (GCR, 1452)
Novo Nordisk A/S

Backup Contact:


Location Contact:

Evansville, Indiana 47710
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.